A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NPM1 / nucleophosmin 1

[Related PubMed/MEDLINE]
Total Number of Papers: 111
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NPM1  (>> Co-occurring Abbreviation)
Long Form:   nucleophosmin 1
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 CircRNA WHSC1 targets the miR-646/NPM1 pathway to promote the development of endometrial cancer. circRNAs
2020 Clinicopathological significance of common genetic alterations in patients with acute promyelocytic leukemia. AML, APL, bcr1, EGFR, FLT3, PCR, PML, WBC
2020 EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53. ALCL, EBP2, NPM-ALK
2020 Flow cytometry in detection of Nucleophosmin 1 mutation in acute myeloid leukemia patients: A reproducible tertiary hospital experience. AML, HRM PCR, MFI
2020 Formation of adenovirus DNA replication compartments and viral DNA accumulation sites by host chromatin regulatory proteins including NPM1. Ad, ViPR
2020 IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. ALCL, ALK, CRISPR, IL10RA
2020 Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. MLL1
2020 Modulation of Amyloidogenic Peptide Aggregation by Photoactivatable CO-Releasing Ruthenium(II) Complexes. ThT
2020 Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). AML, CEBPA, CI, CIR, CSF3R, FLT3-ITD, HR, MRD
10  2020 NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia. AML, CBS, CTCF, NES
11  2020 Nucleophosmin 1 overexpression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma. 18F-FDG, MTV, PET/CT, TLG
12  2020 Proteostasis unbalance of nucleophosmin 1 in Acute Myeloid Leukemia: An aggregomic perspective. AML
13  2020 Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3. AML, CR, CRi, FLT3, HSCT, LFS, OME, OS, R/R, SOME, VAF
14  2020 The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. AML, ITD
15  2019 Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations. AML, BCR-ABL
16  2019 Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60years. allo-HSCT, AML, CEBPA, HR, OS, PRT
17  2019 Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant. AML, FLT3
18  2019 Cellular therapy against public neoantigens. AMLs
19  2019 Cellular Zinc Finger Protein 622 Hinders Human Adenovirus Lytic Growth and Limits Binding of the Viral pVII Protein to Virus DNA. HAdV, HAdVs, ZNF622
20  2019 Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. ---
21  2019 Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. AML, FLT3, ITD
22  2019 Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing. MRD, UMI
23  2019 Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. AML, NPM1mut, pts, tAML, WES
24  2019 Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics. CBM, ETP-ALL
25  2019 Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia. AML, CN, FLT3, PCR
26  2019 Investigation of screening method for DNMT3A mutations by high-resolution melting analysis in acute myeloid leukemia. AML, DNMT3A, FLT3, HRM, ITD, TKD
27  2019 Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. AML, TCR
28  2019 Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy? AML, HLA, MS
29  2019 NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia. AML, FLT3, STAT5, TKD
30  2019 Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study. AML, FLT3, OS, PML-RARA
31  2019 The acute myeloid leukemia-associated Nucleophosmin 1 gene mutations dictate amyloidogenicity of the C-terminal domain. AML, SEM
32  2019 Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Adv, AML, AR, ELN, fav, FLT3, IA, INT, IR
33  2019 [Expression of WT1 gene and its prognostic value in patients with acute myeloid leukemia]. AML, DFS, FLT3-ITD, ORR, OS, WT1
34  2018 Acute Myeloid Leukemia: Is That All There Is? AML, CEBPalpha, CPI, FLT3, LSD1, MRD, NF-kappaB
35  2018 Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia. Cbl, CEBPA, JAK2, KRAS, TET2
36  2018 Establishment of a Multiplex PCR-Based Procedure for Detection of Most Common Mutations in NPM1, FLT3 in Acute Myeloid Leukemia Patients. AML, FLT3
37  2018 Glycogen synthase kinase-3 and alternative splicing. GSK-3
38  2018 Long noncoding RNA HOTAIR mediates the estrogen-induced metastasis of endometrial cancer cells via the miR-646/NPM1 axis. EC, HOX
39  2018 NPM1 Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction. AML, CN-AML, PCR
40  2018 Prevalence and Clinical Significance of FLT3 and NPM1 Mutations in Acute Myeloid Leukaemia Patients of Assam, India. AML, EGFR, FLT3
41  2018 When the good go bad: Mutant NPM1 in acute myeloid leukemia. AML, NK
42  2018 Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: AHokkaido Leukemia Net Study. AML, CEBPA, CN, FLT3-ITD, SNP, WT1
43  2017 A novel phenylphthalimide derivative, pegylated TC11, improves pharmacokinetic properties and induces apoptosis of high-risk myeloma cells via G2/M cell-cycle arrest. CRBN, MM
44  2017 Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. AML, CN, HVs
45  2017 Cancer upregulated gene 2 induces epithelial-mesenchymal transition of human lung cancer cells via TGF-beta signaling. CUG2, EMT
46  2017 FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics. CN-AML, FLT3
47  2017 Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia. AML, PI, wt-NPM1
48  2017 NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. CLL, RNPs, siRNA
49  2017 NPM1 Mutant Mediated PML Delocalization and Stabilization Enhances Autophagy and Cell Survival in Leukemic Cells. AML, PML
50  2017 Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. ---
51  2017 Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. AML, ECM, NET, SPARC
52  2017 Phe354Leu Polymorphism of LKB1 Is a Potential Prognostic Factor for Cytogenetically Normal Acute Myeloid Leukemia. AML, CEBPA, FLT3, IDH1, LKB1
53  2016 Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. ---
54  2016 Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. AML, AVA, CRM1, FLT3, WT
55  2016 Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia. AML, MFC, MRD, RQ-PCR
56  2016 Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission. allo-HSCT, AML, CR, EFS, MRD, OS
57  2016 Regulation of Neuronal Survival by Nucleophosmin 1 (NPM1) Is Dependent on Its Expression Level, Subcellular Localization, and Oligomerization Status. CDKs
58  2016 Role of p14ARF-HDM2-p53 axis in SOX6-mediated tumor suppression. HMG, SOX6
59  2016 The human nucleophosmin 1 mutation A inhibits myeloid differentiation of leukemia cells by modulating miR-10b. AML, NPM1-mA
60  2016 The Wilms Tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia. AML, CIR, FLT3-ITD, HR, NK, OS, SNP, WT1
61  2016 Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer. AA, AUC, BPH, EA, PCa, PSA, ROC, SERPA, TAAs
62  2015 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1). ---
63  2015 A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. MM, TRAP
64  2015 Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia. AML
65  2015 ATRA and ATO team up against NPM1. Abl, AML, APL, ATO, ATRA, bcr
66  2015 Coexpression Pattern Analysis of NPM1-Associated Genes in Chronic Myelogenous Leukemia. CML
67  2015 Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia. AML, PB, PCR
68  2015 Mutated NPM1 in combination with overexpression of Meis1 or Hoxa9 is not sufficient to induce acute myeloid leukemia. AML
69  2015 Novel structural co-expression analysis linking the NPM1-associated ribosomal biogenesis network to chronic myelogenous leukemia. CML
70  2015 Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations. allo, CN-AML, FLT3-ITD, HSCT, OS
71  2015 Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. AML, PML, RA
72  2014 Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications. RT-qPCR
73  2014 Estrogen mediated expression of nucleophosmin 1 in human endometrial carcinoma clinical stages through estrogen receptor-alpha signaling. ERalpha
74  2014 FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from India. AML, APL, FLT3
75  2014 Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology. AMLs, APE1, BER
76  2014 High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemia. AML, EFS, FLT3, FLT3-ITD, FLT3-TKD, HRM
77  2014 Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. CN-AML
78  2014 Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis. AML, DFS, HR, NPM1-mt, NPM1-wt
79  2014 Targeting nucleophosmin 1 represents a rational strategy for radiation sensitization. DSB, MEFs, NSCLC, TMA
80  2014 Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. VPA
81  2013 Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. AML, CNAs, DNMT3Amut, NPM1mut, UPDs
82  2013 Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations. AML, CN-AML, FACS, NK, RQ-PCR
83  2013 Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia. AML, IHC
84  2013 Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD). allo-HCT, AML, CN-AML, HCT
85  2013 Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence. CRC
86  2013 Prognostic Impact of Nucleophosmin 1 (NPM1) Gene Mutations in Egyptian Acute Myeloid Leukemia Patients. PCR-SSCP
87  2013 The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics. allo-SCT, AML, OS
88  2013 [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis]. AML, CE, FLT3
89  2012 Acute myeloid leukemia and transcription factors: role of erythroid Kruppel-like factor (EKLF). AML, CEBPA, EFS, EKLF, FLT3, GATA1, GATA2, OS
90  2012 Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. AML, FLT3, WBC
91  2012 miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death. AML, LNA, NPM1mut
92  2011 Detection of nucleophosmin 1 mutations by quantitative real-time polymerase chain reaction versus capillary electrophoresis: a comparative study. qPCR
93  2011 Gene expression profiling in acute myeloid leukaemia. AML, CEBPA, FAB classification, FLT3-ITD, WHO
94  2011 miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. AML, IR, MDM4, miRNA
95  2011 Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. ATRA
96  2010 A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. AML
97  2010 Detection of exon 12 type A mutation of NPM1 gene in IMS-M2 cell line. ---
98  2010 Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML). AML, LDH, TLC
99  2010 High cytogenetic or molecular genetic risk acute myeloid leukemia. FLT3, ITD
100  2010 Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. AML, CEBPA, CN-AML, CNAs, SNP, UPD